Next-Gen SERD Cuts Breast Cancer Recurrence Risk by 30% in Trial

(MedPage Today) — SAN ANTONIO — In a large Phase III trial of adjuvant treatment of early-stage breast cancer, the investigational oral drug giredestrant reduced the risk of invasive disease recurrence by 30% compared with standard endocrine therapy…